Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 80, Issue 2, pp 363–369 | Cite as

Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients

  • Wan-Su Park
  • Gab-jin Park
  • Seunghoon Han
  • Sooho Ban
  • Moon-Young Park
  • San-ho Kim
  • Seon-Myung Kim
  • Yong-Chul Kim
  • Hyung Sik Kim
  • Young G. Shin
  • Dong-Seok YimEmail author
Original Article
  • 390 Downloads

Abstract

Purpose

AGM-130 is a cyclin-dependent kinase inhibitor that exhibits dose-dependent efficacy in xenograft mouse models. During preclinical pharmacokinetic (PK) studies, mice and rats showed comparable PK parameters while dogs showed unusually high clearance (CL), which has made human PK prediction challenging. To address this discrepancy, we performed a human microdosing PK and developed a mouse PK/PD model in order to guide the first-in-human studies.

Methods

A microdose of AGM-130 was given via intravenous injection to healthy subjects. Efficacy data obtained using MCF-7 breast cancer cells implanted in mice was analyzed using pre-existing tumor growth inhibition models. We simulated a human PK/PD profile with the PK parameters obtained from the microdose study and the PD parameters estimated from the xenograft PK/PD model.

Results

The human CL of AGM-130 was 3.08 L/h/kg, which was comparable to CL in mice and rats. The time-courses of tumor growth in xenograft model was well described by a preexisting model. Our simulation indicated that the human doses needed for 50 and 90% inhibition of tumor growth were about 100 and 400 mg, respectively.

Conclusions

This is the first report of using microdose PK and xenograft PK/PD model to predict efficacious doses before the first-in-human trial in cancer patients. In addition, this work highlights the importance of integration of all of information in PK/PD analysis and illustrates how modeling and simulation can be used to add value in the early stages of drug development.

Keywords

Human microdose Tumor growth inhibition AGM-130 Cyclin-dependent kinase Cancer 

Notes

Acknowledgements

This research was supported by Anygen Co., Ltd.

Compliance with ethical standards

Conflict of interest

Sooho Ban, Moon-Young Park, San-ho Kim, Seon-Myung Kim and Yong-Chul Kim are employed by Anygen Co., Ltd. The other authors have no conflicts of interest to declare.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14(2):130–146. doi: 10.1038/nrd4504 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Krystof V, Uldrijan S (2010) Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 11(3):291–302. doi: 10.2174/138945010790711950 CrossRefPubMedGoogle Scholar
  3. 3.
    Sharma PS, Sharma R, Tyagi R (2008) Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets 8(1):53–75. doi: 10.2174/156800908783497131 CrossRefPubMedGoogle Scholar
  4. 4.
    Mariaule G, Belmont P (2014) Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey. Molecules 19(9):14366–14382. doi: 10.3390/molecules190914366 CrossRefPubMedGoogle Scholar
  5. 5.
    Kim WS, Lee MJ, Kim DH, Lee JE, Kim JI, Kim YC, Song MR, Park SG (2013) 5′-OH-5-nitro-Indirubin oxime (AGM130), an indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells. Leuk Res 37(4):427–433. doi: 10.1016/j.leukres.2012.12.017 CrossRefPubMedGoogle Scholar
  6. 6.
    Ahn MY, Kim TH, Kwon SM, Yoon HE, Kim HS, Kim JI, Kim YC, Kang KW, Ahn SG, Yoon JH (2015) 5-Nitro-5′-hydroxy-indirubin-3′-oxime (AGM130), an indirubin-3′-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo. Eur J Pharm Sci 79:122–131. doi: 10.1016/j.ejps.2015.08.015 CrossRefPubMedGoogle Scholar
  7. 7.
    Kim SA, Kim SW, Chang S, Yoon JH, Ahn SG (2009) 5′-nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells. Cancer Lett 274(1):72–77. doi: 10.1016/j.canlet.2008.08.033 CrossRefPubMedGoogle Scholar
  8. 8.
    Choi SJ, Lee JE, Jeong SY, Im I, Lee SD, Lee EJ, Lee SK, Kwon SM, Ahn SG, Yoon JH, Han SY, Kim JI, Kim YC (2010) 5,5′-substituted indirubin-3′-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem 53(9):3696–3706. doi: 10.1021/jm100080z CrossRefPubMedGoogle Scholar
  9. 9.
    Svendsen P, El-Galaly TC, Dybkaer K, Bogsted M, Laursen MB, Schmitz A, Jensen P, Johnsen HE (2016) The application of human phase 0 microdosing trials: a systematic review and perspectives. Leuk Lymphoma 57(6):1281–1290. doi: 10.3109/10428194.2015.1101097 CrossRefPubMedGoogle Scholar
  10. 10.
    FDA (2006) Guidance for industry, investigators, and reviewers: Exploratory IND studies. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf. Accessed 19 Jun 2017
  11. 11.
    Wong H, Gould SE, Budha N, Darbonne WC, Kadel EE 3rd, La H, Alicke B, Halladay JS, Erickson R, Portera C, Tolcher AW, Infante JR, Mamounas M, Flygare JA, Hop CE, Fairbrother WJ (2013) Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metab Dispos 41(12):2104–2113. doi: 10.1124/dmd.113.053926 CrossRefPubMedGoogle Scholar
  12. 12.
    Yamazaki S, Spilker ME, Vicini P (2016) Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. Expert Opin Drug Metab Toxicol 12(3):253–265. doi: 10.1517/17425255.2016.1141895 CrossRefPubMedGoogle Scholar
  13. 13.
    Salphati L, Wong H, Belvin M, Bradford D, Ka Edgar, Wei W, Sampath D, Wallin JJ (2010) Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel PI3 K Inhibitor 2-(1 H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno [3, 2-d] pyrimidine (GDC-0941). Drug Metab Dispos 38(9):1436–1442. doi: 10.1124/dmd.110.032912 CrossRefPubMedGoogle Scholar
  14. 14.
    Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS, Hop CECA, Gould SE (2012) Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18(14):3846–3855. doi: 10.1158/1078-0432.CCR-12-0738 CrossRefPubMedGoogle Scholar
  15. 15.
    Chen B, Dong JQ, W-j Pan, Ruiz A (2012) Pharmacokinetics/pharmacodynamics model-supported early drug development. Curr Pharm Biotechnol 13(7):1360–1375CrossRefPubMedGoogle Scholar
  16. 16.
    Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148–154. doi: 10.1007/BF00300234 CrossRefPubMedGoogle Scholar
  17. 17.
    Park MH, Lee YY, Cho KH, La S, Lee HJ, Yim DS, Ban S, Park MY, Kim YC, Kim YG, Shin YG (2016) Validation of a liquid chromatography-triple quadrupole mass spectrometric method for the determination of 5-nitro-5′-hydroxy-indirubin-3′-oxime (AGM-130) in human plasma and its application to microdose clinical trial. Biomed Chromatogr 30(3):323–329. doi: 10.1002/bmc.3551 CrossRefPubMedGoogle Scholar
  18. 18.
    Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64(3):1094–1101CrossRefPubMedGoogle Scholar
  19. 19.
    Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093–1095CrossRefPubMedGoogle Scholar
  20. 20.
    Lappin G, Noveck R, Burt T (2013) Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol 9(7):817–834. doi: 10.1517/17425255.2013.786042 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Maeda K, Sugiyama Y (2011) Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev 63(7):532–538. doi: 10.1016/j.addr.2011.02.004 CrossRefPubMedGoogle Scholar
  22. 22.
    Burt T, John CS, Ruckle JL, Vuong LT (2017) Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans—a practical guide. Expert Opin Drug Deliv 14(5):657–672. doi: 10.1080/17425247.2016.1227786 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Wan-Su Park
    • 1
    • 2
  • Gab-jin Park
    • 1
    • 2
  • Seunghoon Han
    • 1
    • 2
  • Sooho Ban
    • 3
  • Moon-Young Park
    • 3
  • San-ho Kim
    • 3
  • Seon-Myung Kim
    • 3
  • Yong-Chul Kim
    • 3
    • 4
  • Hyung Sik Kim
    • 5
  • Young G. Shin
    • 6
  • Dong-Seok Yim
    • 1
    • 2
    Email author
  1. 1.Department of Clinical Pharmacology and TherapeuticsSeoul St. Mary’s HospitalSeoulKorea
  2. 2.PIPET (Pharmacometrics Institute for Practical Education and Training), College of MedicineThe Catholic University of KoreaSeoulKorea
  3. 3.Division of Drug DiscoveryAnygen Co., LtdGwangjuKorea
  4. 4.School of Life SciencesGwangju Institute of Science and TechnologyGwangjuKorea
  5. 5.School of PharmacySungkyunkwan UniversitySuwonKorea
  6. 6.College of PharmacyChungnam National UniversityDaejeonKorea

Personalised recommendations